Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study

European Journal of Nuclear Medicine and Molecular Imaging
T SchumacherA Merlo

Abstract

We have previously presented preliminary observations on targeting somatostatin receptor-positive malignant gliomas of all grades by local injection of the radiolabelled peptidic vector 90Y-DOTATOC. We now report on our more thorough clinical experience with this novel compound, focussing on low-grade and anaplastic gliomas. Small peptidic vectors have the potential to target invisible infiltrative disease within normal surrounding brain tissue, thereby opening a window of opportunity for early intervention. Five progressive gliomas of WHO grades II and III and five extensively debulked low-grade gliomas were treated with varying fractions of 90Y-DOTATOC. The vectors were locally injected into the resection cavity or into solid tumour. The activity per single injection ranged from 555 to 1,875 MBq, and the cumulative activity from 555 to 7,030 MBq, according to tumour volumes and eloquence of the affected brain area, yielding dose estimates from 76+/-15 to 312+/-62 Gy. Response was assessed by the clinical status, by steroid dependence and, every 4-6 months, by magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography. In the five progressive gliomas, lasting responses were obtained for at least...Continue Reading

Citations

Feb 6, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Marion de JongEric P Krenning
Jul 13, 2006·European Journal of Nuclear Medicine and Molecular Imaging·Marta CremonesiGiampiero Tosi
Feb 1, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Stefan KneifelAdrian Merlo
Jun 10, 2004·Cancer Biotherapy & Radiopharmaceuticals·Asa Liljegren SundbergVladimir Tolmachev
Sep 30, 2004·Cancer Biotherapy & Radiopharmaceuticals·Vladimir TolmachevLars Gedda
Mar 7, 2013·Cancer Biotherapy & Radiopharmaceuticals·Clément MorgatPhilippe Fernandez
Nov 24, 2005·AJR. American Journal of Roentgenology·Christian A TaschnerErnst W Radue
Jan 15, 2005·Journal of Receptor and Signal Transduction Research·Alex N EberleSylvie Froidevaux
Jun 8, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·Anna HelbokClemens Decristoforo
May 22, 2004·Annals of the New York Academy of Sciences·Eric P KrenningMarion De Jong
Jun 23, 2012·International Journal of Pharmaceutics·Daniela AllhennAlf Lamprecht
Aug 11, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Miklos PlessJan Mueller-Brand
Jun 13, 2017·Neuro-oncology·Norbert GalldiksJörg C Tonn
Apr 15, 2004·British Journal of Cancer·M R Zalutsky
Aug 16, 2003·Endocrine Reviews·Jean Claude Reubi
Aug 4, 2019·Pharmaceutics·Janik PuttemansNick Devoogdt
May 2, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Leszek KrolickiAlfred Morgenstern
Sep 9, 2018·Acta Neuropathologica Communications·Romain AppayUNKNOWN POLA network
Dec 1, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Leszek KrólickiAlfred Morgenstern
Jun 17, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stefan KneifelAdrian Merlo
Dec 22, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Valentina AmbrosiniHelmut R Maecke
Feb 13, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Dirk HeuteIrene J Virgolini
Jul 19, 2021·European Journal of Radiology·Fulvio ZaccagnaFerdia A Gallagher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Related Papers

Neurosurgery Clinics of North America
Rudolf Fahlbusch, Christopher Nimsky
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer
Thorsten D PoeppelChristian Boy
© 2022 Meta ULC. All rights reserved